ArticleInternational journal of chronic obstructive pulmonary disease2015
Proteoglycan 4 is a diagnostic biomarker for COPD.
Article in International journal of chronic obstructive pulmonary disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02764658 (Studies in Pulmonary Inflammation and the Effectiveness of Pulmonary Recovery in COPD Patients：the Mechanism of Proteoglycan 4), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Studies in Pulmonary Inflammation and the Effectiveness of Pulmonary Recovery in COPD Patients：the Mechanism of Proteoglycan 4
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Multi-omics integration predicts the incidence of 17 diseases in the UK Biobank.Nature communications · 2026Article
- Tamoxifen promotes metastasis of breast cancer via reshaping lipid-driven fibrotic microenvironments in the lung.Neoplasia (New York, N.Y.) · 2026Article
- Proteoglycan-4 (PRG4) serum concentration is lower in aged mice, and genetic deficiency impacts survival probability, blood parameters, and bone during aging.GeroScience · 2026Article
- Proteomic profiling of extracellular vesicles derived from human serum for the discovery of biomarkers in Avascular necrosis.Clinical proteomics · 2024Article
- Proteomics Clustering Research of ITRAQ Markers in Plasma of AIDS Patients with Different Chinese Medicine Syndromes.Iranian journal of public health · 2024Article
- Plasma proteoglycan 4: a novel biomarker for acute lung injury after pediatric cardiac surgery.Translational pediatrics · 2023Article
- Biomarkers for Adverse Lung Injury Following Pediatric Cardiopulmonary Bypass.Critical care explorations · 2021Article
- The Effect of Intense Exercise on Equine Serum Proteoglycan-4/Lubricin.Frontiers in veterinary science · 2020Article
- Nanodiamond for Sample Preparation in Proteomics.Analytical chemistry · 2019Article
- Streptococcal Siglec-like adhesins recognize different subsets of human plasma glycoproteins: implications for infective endocarditis.Glycobiology · 2018Article
- Neonatal hyperoxia depletes pulmonary vein cardiomyocytes in adult mice via mitochondrial oxidation.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Genotype-Phenotype Associations of IL6 and PRG4 With Conjunctival Fibrosis After Glaucoma Surgery.JAMA ophthalmology · 2017Article
- Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2017Article
- Prognostic utility of admission cell-free DNA levels in patients with chronic obstructive pulmonary disease exacerbations.International journal of chronic obstructive pulmonary disease · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe measurement of C-reactive protein (CRP) to confirm the stability of COPD has been reported. However, CRP is a systemic inflammatory biomarker that is related to many other diseases.
objectiveThe objective of this study is to discover a diagnostic biomarker for COPD.
methodsSixty-one subjects with COPD and 15 healthy controls (10 healthy non-smokers and 5 smokers) were recruited for a 1-year follow-up study. Data regarding the 1-year acute exacerbation frequency and changes in lung function were collected. CRP and the identified biomarkers were assessed in the validation COPD cohort patients and healthy subjects. Receiver operating characteristic values of CRP and the identified biomarkers were determined. A validation COPD cohort was used to reexamine the identified biomarker. Correlation of the biomarker with 1-year lung function decline was determined.
resultsProteoglycan 4 (PRG4) was identified as a biomarker in COPD. The serum concentrations of PRG4 in COPD Global initiative for chronic Obstructive Lung Disease (GOLD) stages 1+2 and 3+4 were 10.29 ng/mL and 13.20 ng/mL, respectively; 4.99 ng/mL for healthy controls (P<0.05); and 4.49 ng/mL for healthy smokers (P<0.05). PRG4 was more sensitive and specific than CRP for confirming COPD severity and acute exacerbation frequency. There was no correlation between CRP and PRG4 levels, and PRG4 was negatively correlated with the 1-year change in predicted forced vital capacity percent (R (2)=0.91, P=0.013).
conclusionPRG4 may be a biomarker for identification of severity in COPD. It was related to the 1-year forced vital capacity decline in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.